# Freshworks

Type: Company (FRSH)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/freshworks
Canonical HTML page: https://getbiobrief.com/entity/freshworks

## Recent coverage (1 stories)

### Veeva Systems Drops 5.3% in Tech Sell-Off—A Buying Opportunity for Pharma SaaS?
2026-08-04 19:06:32 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Veeva Systems (VEEV) fell 5.3% to $201.56 during a broader software rout triggered by the Federal Reserve’s hawkish dot plot. The life-sciences cloud leader faces the same rate-driven multiple compression as other SaaS names, but its pharma client base and mission-critical R&D applications may insulate revenue, creating a potential long-term entry point for biotech investors.
Full story: https://getbiobrief.com/story/veeva-systems-fed-selloff-biotech-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.